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Abstract
Background: Radiation therapy is a well-recognized, effective modality used for palliative care. Most studies
completed to date have endpoints of one month or greater after treatment completion. This study analyzed the
response rates at different time points during the first month after treatment.
Methods: From May 2010 to November 2011, 61 patients treated for 74 metastases were included in the study.
The end points were defined as the completion of treatment (CT) and d8, d15 and d30 after the completion of
treatment. The response rate was measured by the worst pain in the last 24 hours and the administered opioid
dose. Patient assessment was performed during consultations and phone appointments.
Results: The overall response rate significantly improved from the CT (38%) to d8 (53.8%), d15 (53.8%) and d30
(57.1%) (respectively p < 0.001; p < 0.001 and p = 0.001). The improvement peaked at d8. Patients responding to the
treatment at d8 had a significative longer pain relapse free survival (PRFS) compared to patients not responding
(3.38 weeks vs 0.3 weeks; p < 0.001). From the beginning of treatment to the CT and at d8 , d15 and d30, oral
morphine equivalent dose (OMED) did not significantly differ. However, the pain decrease did not result in a
performance status improvement, which declined over time (p < 0.001).
Conclusion: Radiation therapy is an efficient treatment method for providing pain relief. This relief peaked at d8
after treatment, and the response at d8 is predictive of the response at 4 weeks. Pain management alone is not
enough to improve performance status; further studies are needed to evaluate a more global supportive care
approach.
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Background
Approximately 50% of patients with cancer present metas-
tases at the initial presentation or at relapse. Bone is one
of the most frequent metastasis locations, particularly for
lung, breast, and prostate cancers. Pain is the most com-
mon and debilitating symptom of bone metastases. Pain
alters patient quality of life and requires specific support.
This support includes motor function improvement and
local or systemic treatment. Treatment may consist of the
concomitant or alternate administration of analgesics,
chemotherapy, hormone therapy, bisphosphonates, sur-
gery, interventional radiology, and radiotherapy.
External beam irradiation for painful bone metastases
has been well established by many prospective trials and
can lead to pain relief and/or reduce analgesic consump-
tion. Several radiation treatment schedules with similar
effectiveness have been described. The most used sched-
ules deliver 30 Gy in 10 fractions of 3 Gy, 20 Gy in 5
fractions of 4 Gy or a single fraction of 8 Gy [1-7]. An
updated meta-analysis did not find any differences in the
overall response rates between multi- and single frac-
tionation (61% and 60%, respectively) [8]. Stereotactic
beam radiation therapy (SBRT) and intensity-modulated
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radiotherapy (IMRT) have proved their effectiveness in
spinal bone metastasis irradiation and re-irradiation
[9-12]. A recent review showed that local control was
achieved in 87% of cases [13].
The response to irradiation has been evaluated using
many different types of measure. Visual analogue scales,
a numeric scale, a Brief Pain Inventory, the dose of anal-
gesics and the requirement for re-irradiation are the
most frequently used [14]. Furthermore, the follow-up
evaluation period after the completion of radiotherapy is
variable in all trials and retrospective studies. Currently,
evaluations at one or two months after irradiation com-
pletion are used to predict the definitive response to
radiotherapy. However, this waiting time can be consid-
ered as too long to efficiently manage painful metastasis
using re-irradiation, particularly as the life expectancy of
these patients is short.
In this study, we report the response rate at the end of
treatment and one, two and four weeks after treatment
to determine whether an earlier evaluation could predict
a definitive response.
Methods
From May 2010 to October 2011, patients referred to
the radiation department of the Regional Cancer insti-
tute Paul Strauss for painful bone metastases were eli-
gible to participate in this study examining the response
after irradiation. The inclusion criteria were age above
18, ability to understand and speak French and consent
to participate to the study. This study was approved by
our institutional review board (committee against pain
CLUD). Patients who underwent previous surgery,
cementoplasty, or in-field irradiation and remained in
pain were also included. Clinical evaluations were
performed at the first radiotherapy consultation (begin-
ning of treatment, BT) and at the completion of treat-
ment (CT). Patients provided informed consent. A visual
analogue scale (VAS) strip was given to each patient to
evaluate their pain at home after being instructed on
how to use it. On days 8, 15 and 30 after the CT, evalua-
tions were performed during a scheduled phone ap-
pointment. The interviewer (PT) used a home survey to
obtain the patient information.
The information collected at the first consultation in-
cluded age, gender, primary cancer location, pathology,
painful bone metastasis location, performance status,
steroid treatment, analgesic morphine taken in the last
24 hours converted to the oral morphine equivalent dose
(OMED) and local treatments received previously [15].
On d8, d15 and d30, OMED, performance status, and
the minimum, mean and maximal pain evaluations in
the past 24 hours (assessed using the VAS) were
reported. The adverse effects of radiation therapy were
reported according to the CTCAE v4. Patients who did
not answer the phone were considered missing but were
not excluded from the study.
The radiotherapy response rates were evaluated using
the international bone metastases consensus group
(IBMCG) criteria (Table 1).
The treatment was performed using linear accelerators
with 6 MV or 15 MV photon beams. The TomoTherapy
Hi-ART and Novalis TX systems were used for IMRT
and SBRT treatment planning. The time period between
the first consultation and the first irradiation session did
not exceed 2 weeks.
Statistical analysis
The response rates at the different end points were com-
pared for each patient: i) between the BT and CT, BT- d8,
BT-d15 and BT-d30, ii) between the CT and d8, CT- d15
and CT-d30 iii) between d8- d15 and d8-d30, iv) between
d15 and d30. Only patients with an available response rate
at the compared end points were analyzed, and if the in-
formation was missing, the patient was excluded from the
statistical analysis at the corresponding end point.
Responders were patients with a complete response (CR)
or a partial response (PR); patients with stable disease
(SD), progressive disease (PD) and undetermined responses
(UR) were considered as non-responders. The distributions
of the Karnofsky performance status (KPS) (< 70% and ≥
70%) and World Health Organisation performance status
(WHO PS) (<2 and ≥ 2) at each evaluation were analyzed
by the χ2 test. The nonparametric Wilcoxon test was used
to compare repeated measures of pain score and OMED.
A pain relapse free survival (PRFS) was calculated for the
patients responding at every end points from the CT to
d30 (range from 0 to 4 weeks). PRFS was analysed using a
Kaplan Meyer method. p <0.05 was considered significant.
Data were analyzed using SPSS version 20 (IBM Software).
Table 1 The response rate to radiotherapy according to
the IBMCG criteria
Responders
CR Pain reduction by two scores or more to zero and OMED stable or
reduced
PR Pain reduction by two scores or more and OMED stable or
reduced
Stable pain and OMED reduction by 25% or more
Non-responders
PD Pain increase by two scores or more and OMED stable or increased
No change in pain and OMED increased by 25% or more (or start
of morphine use after baseline)
SD Stable pain and stable OMED
UR Other cases
Abbreviations: CR: complete response; PR: partial response; PD: progressive
disease; SD: stable disease; UR: undetermined response.
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Results
Between May 2010 and November 2011, 61 patients
were enrolled in the study. The general characteristics of
the patients are summarized in Table 2. These 61 pa-
tients were treated for 74 metastatic locations: 31 were
spinal (42%), 21 were pelvic (28%), 10 were long bones
(13%) 8 were scapula (11%), 3 were rib, and 1 was man-
dibular. Forty-nine patients were treated for one meta-
static location (80%), 11 for two (18%) and 1 patient for
three.
Forty-nine metastatic sites were not treated previously
(66%). Twenty five metastases were treated before the
present irradiation, within a minimum of one month.
Ten metastases (14%) were operated on (decompressive,
stabilization), 9 (12%) received cementoplasty, 5 (7%)
were irradiated, and 1 patient underwent surgery and
radiotherapy. The six patients who previously received
irradiation presented metastases located in spine for four
and in pelvis for two metastases. The irradiation sched-
ules before re-irradiation were 8 Gy in a single fraction
(one patient), 24 Gy in 6 fractions of 4 Gy (one patient),
30 Gy in 10 fractions of 3 Gy (two patients), and 36 Gy
in 12 fractions of 3 Gy (two patients).
Concerning the current irradiation, 66 bone metasta-
ses (89%) were treated with 3D conformational radio-
therapy. Seven spinal metastases (9.5%) were treated
with SBRT (re-irradiation in 4 cases). One metastasis
was treated with IMRT. For 62 treatments (91%), the
dose schedules were 8 Gy in a single fraction, 20 Gy in 5
fractions of 4 Gy and 30 Gy in 10 fractions of 3 Gy. The
SBRT dose was 23.31 Gy in 3 fractions of 7.77 Gy deliv-
ered on days 1, 3 and 5. Other fractionations were pro-
posed in 5 patients.
All patients included completed the treatment, and an
evaluation at the completion of treatment was per-
formed in 50 patients (82%). On days 8, 15 and 30, eval-
uations were obtained from 39 (64%), 39 (64%), and 42
(69%) patients, respectively. The reasons for no reply in-
cluded unreachable by phone, death or refusal to con-
tinue the study (Table 3). Patients not responding at d30
had a statistically significant worse WHO-PS (3 vs 2;
p = 0.018), but age, gender, VAS and OMED weren’t sta-
tistically different. The response rate to the treatment,
median worst pain, median WHO-PS, KPS and OMED
are presented in Tables 4 and 5.
Analysis of visual scale
Using the visual scale, the patients had a significant de-
crease in the median maximal pain from the BT to the
CT from VAS 7 to VAS 5, respectively (p = 0.001). From
the BT to d8, d15 and d30, the VAS decreased to 3 and
remained statistically significant (p < 0.001 at each evalu-
ation). There was no significant difference in the max-
imal VAS from the CT to d8, d15 or d30 (p = 0.115;
p = 0.088; p = 0.072, respectively), from d8 to d15 or d30





Gender Median KPS (min-max) at BT 70 (30–100)
Male 37 60.7 Median WHO-PS(min-max) at BT 2 (0–4)
Female 24 39.3 Treatment before RT
Median Age (min-max) 65 (43–88) Surgery 10 13.6
Primary cancer site Cementoplasty 9 12.2
Lung and pleura 20 32.8 RT 5 6.8
Breast 12 19.7 RT/Surgery 1 1.4
Kidney, prostate 10 16.4 No treatment 49 66.1
Gastrointestinal 7 11.4 Radiation treatment modality
Head & Neck 3 4.8 30 Gy; 10 × 3 Gy 41 55.4
Unknown 2 3.2 20 Gy; 5 × 4 Gy 14 18.9
Other 7 11.4 8 Gy; 1 × 8 Gy 6 8.1
Metastases localization 23.31 Gy; 3 × 7.77 Gy 7 9.5
Spinal 31 41.9 Other 6 8.1
Pelvis 21 28.4 Number of metastases
Long bone 10 13.5 1 49 80
Scapula 8 10.8 2 11 18
Other 4 5.4 3 1 2
Abbreviations: KPS: karnofsky performance status; RT: radiotherapy; WHO PS: world health organization performance status.
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(p = 0.441 and p = 0.393, respectively) or from d15 to
d30 (p = 0.345).
Analysis of OMED
The OMED did not significantly differ between each
interval of evaluation. The mean OMEDs at the BT, the
CT, d8, d15 and d30 were 40 mg, 40 mg, 30 mg, 30 mg
and 40 mg, respectively (p = 0.93 between BT and CT,
p = 0.64, for CT-d8, p = 0.47 for CT-d15, p = 0.96 for
CT-d30 and p = 0.96 for BT-d30).
Analysis of IBMCG
The overall response rates at CT, d8, d15 and d30 were
38%; 53.8%; 53.8% and 57.1% respectively. The CR rates
at CT, d8, d15 and d30 were 8%, 10.3%, 15.3% and 16.7%
respectively. Using the IBMCG criteria, there were sig-
nificant improvements (CR, PR) from the CT to d8, d15
and d30 (p < 0.001; p < 0.001 and p = 0.001, respectively),
from d8 to d15 and d30 (p < 0.001 and p = 0.001, re-
spectively), and from d15 to d30 (p = 0.002). Univariate
analysis using Kaplan Meyer method highlighted PRFS
for patients having a response at d8 was significantly im-
proved compared to patients not responding: respect-
ively 3,38 weeks vs 0,3 weeks (p < 0,001). This result
suggests response at d8 is predictive of response at d30.
Performance status (WHO PS and KPS)
Compared to the BT, WHO PS and KPS were signifi-
cantly decreased at the CT, d8 and d30 (p < 0.001). How-
ever, at d15, the data showed a transitory improvement
in WHO-PS and KPS (p < 0.001).
Irradiation side effects
The side effects of radiotherapy included dermatitis,
nausea, vomiting, diarrhea and dysphagia in 11 patients
(18%) at the CT, 9 (15%) patients at d8, 9 (15%) patients
at d15 and 9 (15%) patients at d30 (Table 6). According
to CTCAE v4, only one patient developed grade 3 tox-
icity at the CT and d8; the remaining patients experi-
enced grade 2 or less toxicities. After d8, the toxicities
were grade 2 or less.
Discussion
Several consensus task forces have attempted to recom-
mend tools or methods for following and evaluating
patients with bone metastases [16,17]. One of the rec-
ommendations was to assess pain at 2 months after the
CT [18]. However, we believe that this amount of time is
too long for patients in pain who may have a short life
expectancy. Our study clearly showed that an evaluation
at d8 is sufficient for proposing re-irradiation or another
treatment for remaining painful metastases, as patients
not responding at this end point have significantly lower
PRFS. Another proposal was to perform re-irradiation
at least one month after the previous irradiation. How-
ever, with new techniques, such as IMRT or SBRT,
which can shield organs at risk (particularly the spinal
cord), a higher efficient dose can be delivered, dramatic-
ally increasing the chance of controlling pain with a very
low risk of complications.
This study showed phone evaluation’s feasibility to as-
sess response to an antalgic irradiation, in order to be
able to propose an adequate care of the pain. This
method allows the assessment of patients at home,
which is more comfortable and avoids travel. Phone
evaluations can be performed by a radiation oncologist
or a trained nurse. In 2004, a study assessing 830 pa-
tients by phone retrieved a higher percent of patients
reachable by phone at 4 weeks (57%) after treatment
completion with a steady decrease through 12 weeks
(48%) [19]. Our results are comparable to that study,
with 72% of patients reachable at the CT and 64-69% at
d8, d15 and d30. As in a previously published series, the
main cause of no reply was death or hospitalization [19].
In 2004, Chow and al. analyzed 580 patients’ response
rates to radiation therapy using pain intensity scale and
analgesic consumption [20]. In this study the overall
Table 3 The reasons for non-evaluation
CT D8 D15 D30
Unreachable by phone 11 (12.1%) 20 (32.8%) 20 (32.8%) 13 (21.7%)
Dead 0 1 1 5 (8.3%)
Refusal to continue the study 0 1 1 1
# of patients 11 (18%) 22 (36.1%) 22 (36.1%) 19 (31.1%)
Abbreviations: CT: completion of treatment.
Table 4 Response rates
CT D8 D15 D30
Responders 19 (38%) 21 (53.8%) 21 (53.8%) 24 (57.1%)
CR 4 (8%) 4 (10.3%) 6 (15.3%) 7 (16.7%)
PR 15 (30%) 17 (43.5%) 15 (38.5%) 17 (40.4%)
Non-responders 31 (62%) 18 (46.2%) 18 (46.2%) 18 (42.9%)
SD 20 (40%) 12 (30.8%) 10 (25.8%) 7(16.7%)
PD 7 (14%) 4 (10.3%) 6 (15.3%) 7 (16.7%)
UR 4 (8%) 2 (5.1%) 2 (5.1%) 4 (9.5%)
Total patients 50 39 39 42
Abbreviations: CR: complete response; PR: partial response; PD: progressive
disease; SD: stable disease; UR: undetermined response.
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response rates at 1, 2 and 4 weeks were 41%, 41% and
39% respectively. The CR rates at 1, 2 and 4 weeks were
32%, 28% and 26% respectively. In our study the overall
response rates at 1,2 and 4 weeks were 38%, 53.8%,
53.8% and 57.1% respectively and CR at 1,2 and 4 weeks
were 8%, 10.3%, 15.3%, and 16.7%. Our results are
comparable to previously published results using the
same evaluation method (IBMCG) [20] and time at
evaluation (one month) [21].
Despite the improvement of the overall response to
pain after radiation therapy, our study showed a worsen-
ing of the performance status. Patients had an altered
Table 5 The intensity of the worst pain, OMED, performance status, and Karnofsky index at baseline, the CT, d8, d15
and d30 after radiotherapy treatment
BT Evaluation time Results P*
Median worst pain (range) 7 (1–10) CT 5 (0–10) 0.001
D8 3 (0–10) <0.001
D15 3 (0–10) <0.001
D30 3 (0–10) <0.001
Median/Mean OMED (mg) (range) 40/90 (0–920) CT 40/111.1 (0–720) 0.93
D8 30/65.7 (0–380) 0.64
D15 30/75.9 (0–480) 0.47
D30 40/91.2 (0–570) 0.96
WHO PS (range) 2 (0–4) CT 2 (0–4) 0.003
D8 2 (0–4) 0.004
D15 2 (0–4) 0.011
D30 2 (0–4) 0.003
KPS (range) 70 (30–100) CT 70 (30–100) 0.001
D8 70 (30–90) 0.001
D15 70 (30–100) 0.006
D30 70 (30–100) 0.002
Abbreviations: BT: beginning of treatment; CT: completion of treatment; KPS: karnofsky performance status; OMED: oral morphine equivalent dose; WHO PS: world
health organization performance status.
Table 6 Radiation therapy side effects at different end points
CT (# patients) D8 (# patients) D15 (# patients) D30 (# patients)
Nausea,vomiting 3 2 1 1
Grade 1 2 1 1 1
2 0 1 0 0
3 1 0 0 0
Diarrhea 2 1 2 2
Grade 1 1 0 2 2
2 1 1 0 0
3 0 0 0 0
Dysphagia 5 5 5 5
Grade 1 3 1 4 4
2 2 3 1 1
3 0 1 0 0
Dermatitis 1 1 1 1
Grade 1 1 1 1 1
2 0 0 0 0
3 0 0 0 0
Total 11 9 9 9
Abbreviations CT: completion of treatment.
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performance status with a median WHO PS of 2 (0–4)
at the BT. In several previous studies and trials, most pa-
tients had a WHO PS ≥ 2 [4,5]. Unfortunately, patients
with a very poor performance status at the BT, have a
low probability of improving their performance status
because many factors contribute to this status. However,
one study showed that such patients with a short life ex-
pectancy may benefit from analgesic irradiation [22].
This study has some limitations: the population is
mixed concerning metastatic localization, performance
status, radiation therapy schedule, and radiation tech-
nique (RTC 3D or SBRT).
Conclusions
The prospective study demonstrated that radiation ther-
apy is a quick and efficient treatment of bone metastasis
pain. A phone evaluation of pain relief is feasible in
practice. The evaluation of pain at d8 after the CT is
predictive of pain relief thereafter. Thus, if needed, treat-
ment decisions can be made earlier in the patient’s dis-
ease course. However, a good pain response is not
strictly correlated to performance status.
Abbreviations
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